Specialty drugs are biologics—"drugs derived from living cells"—that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions like cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease, and hepatitis C. Specialty drugs are often biologics—"drugs derived from living cells"—that are oral medications. As soon as possible, patients should receive the right medicine. Some businesses have personalized treatment groups that are obviously highly passionate about the topic, even though they may go by the moniker "advances in genetic organizations" or "stratified medicine" groups. However, recent research that looked into the worldwide drug pipeline inventory of around 20 large businesses found that relatively few of them had what may be called stratified or customized medication. We have been striving to put that framework in place. Personalized medicine concepts have been or are now being included within early drug development advice, which will eventually be used to affect policy on patient screening or clinical trial strategies in later phases.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia